Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma
DOI:10.3969/j.issn.1001-5256.2021.03.040
- VernacularTitle:非编码RNA在索拉非尼治疗肝细胞癌耐药中的作用机制
- Author:
Guoxiang CHEN
1
;
Mo ZHOU
;
Sheng CHEN
;
Yuan WANG
;
Yuanlong ZHOU
;
Jihong YANG
Author Information
1. Department of Hepatobiliary Surgery, The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, China
- Publication Type:Research Article
- Keywords:
Carcinoma, Hepatocellular;
RNA, Untranslated;
Sorafenib;
Drug Resistance, Neoplasm
- From:
Journal of Clinical Hepatology
2021;37(3):699-703
- CountryChina
- Language:Chinese
-
Abstract:
Sorafenib, as the first-line treatment drug for advanced hepatocellular carcinoma (HCC), can effectively improve the prognosis of patients with HCC, but sorafenib resistance has become a major obstacle to the therapeutic outcome of HCC. Recent studies have shown that non-coding RNA plays a key role in sorafenib resistance in HCC. This article summarizes that non-coding RNA regulates the sensitivity of HCC to sorafenib by inducing the autophagy of hepatoma cells, promoting the proliferation of liver cancer stem cells, promoting the EMT process of hepatoma cells, inhibiting the apoptosis of hepatoma cells, and regulating the microenvironment of liver cancer tissue. It is pointed out that the molecular mechanism of non-coding RNA in regulating sorafenib resistance in HCC has potential clinical significance in overcoming sorafenib resistance in HCC.
